2-Methylbutyroylcarnitine | 31023-25-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-Methylbutyroylcarnitine
• 英文别名: 3-(2-methylbutanoyloxy)-4-(trimethylazaniumyl)butanoate
• CAS: 31023-25-3
• 化学式: C12H23NO4
• 分子量: 245.32
• InChiKey: IHCPDBBYTYJYIL-UHFFFAOYSA-N

物化性质

• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  66.4
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2923900090

文献信息

• [EN] DIAGNOSTIC METHODS, THERAPEUTIC AGENTS AND USES THEREOF<br/>[FR] PROCÉDÉS DE DIAGNOSTIC, AGENT THÉRAPEUTIQUES ET LEURS UTILISATIONS
  申请人：METABOLON INC

  公开号：WO2018022866A1

  公开（公告）日：2018-02-01

  The present invention provides a compound of formula (I) or a salt thereof and their use as a biomarker in assessing or monitoring kidney function in a subject, determining predisposition to developing reduced kidney function, classifying a subject according to level of kidney function, diagnosing or monitoring chronic kidney disease. Compositions and method of making of the compound of formula (I) are also described.

  本发明提供了化合物(I)或其盐，并将其用作生物标志物来评估或监测受试者的肾功能，确定发展肾功能减退的易感性，根据肾功能水平对受试者进行分类，诊断或监测慢性肾病。还描述了化合物(I)的组成和制备方法。
• [EN] COMPOUNDS, REAGENTS, AND USES THEREOF<br/>[FR] COMPOSÉS, RÉACTIFS ET UTILISATIONS ASSOCIÉES
  申请人：METABOLON INC

  公开号：WO2019067699A1

  公开（公告）日：2019-04-04

  The present invention provides a compound of formula (I), formula (II), formula (III), (IV) or a salt thereof, compositions and methods of making the compound, methods and reagents for measuring the compound, and kits using the same. The use of a compound of formula (I), formula (II), formula (III), or formula (IV) for assessing or monitoring kidney function in a subject, determining predisposition to developing reduced kidney function, classifying a subject according to level of kidney function, and diagnosing or monitoring chronic kidney disease is also described.

  本发明提供了式(I)、式(II)、式(III)、(IV)或其盐的化合物，以及制备该化合物的组合物和方法，测定该化合物的方法和试剂，以及使用该化合物的工具包。还描述了使用式(I)、式(II)、式(III)或式(IV)的化合物来评估或监测受试者的肾功能，确定发展肾功能减退的易感性，根据肾功能水平对受试者进行分类，以及诊断或监测慢性肾脏疾病。
• METHODS FOR USING AND BIOMARKERS FOR AMPK-ACTIVATING COMPOUNDS
  申请人：Hitoshi Yasumichi

  公开号：US20150087673A1

  公开（公告）日：2015-03-26

  Disclosed are methods of using AMPK-activating compounds, for example, in the treatment of cancer and disorders of vascular flow. Also disclosed are biomarkers for AMPK and uses thereof, for example, in the diagnosis and treatment of AMPK-linked disorders. In certain embodiments, the AMPK-activating compounds have the structural formula wherein E, J, T, D 1 , D 2 , D 3 , the ring system denoted by “B”, T, R 3 , R 4 , w and x are as described herein.

  本文公开了使用AMPK激活化合物的方法，例如在癌症和血管流动障碍的治疗中的应用。还公开了AMPK的生物标志物及其用途，例如在AMPK相关疾病的诊断和治疗中的应用。在某些实施例中，AMPK激活化合物具有以下结构式，其中E、J、T、D1、D2、D3、由“B”表示的环系统、T、R3、R4、w和x如本文所述。
• METHODS OF TREATING DISEASES AND DISORDERS RESULTING FROM BETA CORONAVIRUS INFECTION
  申请人：T3D Therapeutics, Inc.

  公开号：US20210369680A1

  公开（公告）日：2021-12-02

  This disclosure describes the use of indane acetic acid derivatives which are PPAR agonists, including PPAR delta, PPAR gamma, and dual PPAR delta and gamma agonists, and which penetrate the blood brain barrier to achieve effective brain to plasma drug levels at non-toxic doses, for the treatment of betacoronavirus diseases, such as COVID-19 and COVID-19 related co-morbid diseases, including Acute Respiratory Distress and CNS disorders, such as delirium and cognitive impairment.

  本公开说明了使用indane乙酸衍生物作为PPAR激动剂，包括PPAR delta，PPAR gamma和双重PPAR delta和gamma激动剂，这些激动剂穿过血脑屏障，在非毒性剂量下实现有效的脑血浆药物水平，用于治疗β冠状病毒疾病，如COVID-19和COVID-19相关的共病疾病，包括急性呼吸窘迫和中枢神经系统疾病，如谵妄和认知障碍。
• Use of L-carnitine derivatives for the manufacture of a medicament for the therapeutical treatment of peripheral neuropathies
  申请人：Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.

  公开号：EP0376899A2

  公开（公告）日：1990-07-04

  The use is disclosed of compounds of general formula wherein: Y is hydrogen, methyl or amino, and R is an unsubstituted or substituted alkyl group selected from methyl, ethyl, 1-methylpropyl, isobutyl, isopropyl, mercaptomethyl and 3-guanidinopropyl and the pharmacologically acceptable salts thereof, for treating degenerative alterations of the nervous system. The compounds can be administered orally or parenterally.

  公开了通式如下的化合物的用途 其中 Y 是氢、甲基或氨基，以及 R 是选自甲基、乙基、1-甲基丙基、异丁基、异丙基、巯基甲基和 3-胍基丙基的未取代或取代的烷基。 及其药理上可接受的盐类，用于治疗神经系统的退行性改变。这些化合物可以口服或肠外给药。